Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Gracell to Start China Trial of CAR-T in Leukemia Patients

publication date: Jan 19, 2021

Suzhou's Gracell Biotech will start a China trial of its FasTCAR cell therapy in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia (B-ALL). GC019F modifies a patient's own T-Cells to express CD19 via a Gracell process that reduces manufacturing time from an average of four weeks to 22 to 36 hours. Gracell believes its platform produces less exhausted, more potent CAR-T cells than the competition. Last week, Gracell said it will start a US trial of a donor-derived CAR-T candidate, also in B-ALL patients. More details....

Stock Symbol: (NSDQ: GRCL)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021